23.054
Bearbeitungen
Änderungen
Hydraziniumsulfat (Quelltext anzeigen)
Version vom 22. September 2009, 19:17 Uhr
, 19:17, 22. Sep. 2009→Patentanmeldung
==Patentanmeldung==
==Patentanmeldung==
DE3889912T2 vom 01.12.1994 EP-0354917. Titel VERFAHREN ZUR VERLÄNGERUNG DES LEBENS KREBSERKRANKTER MENSCHEN MITTELS HYDRAZINSULFAT.
DE3889912T2 vom 01.12.1994 EP-0354917. Titel VERFAHREN ZUR VERLÄNGERUNG DES LEBENS KREBSERKRANKTER MENSCHEN MITTELS HYDRAZINSULFAT.
==Literatur==
*Green Saul. Hydrazine sulfate: is it an anticancer agent? Scientific review of alternative medicine 1997;1:19-21.
*Jenks S. Hydrazine sulfate ad is "offensive." Journal of the National Cancer Institute 1993 Apr 7;85(7):528-529.
*Kaegi E., on behalf of the Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. Unconventional therapies for cancer: 4. Hydrazine sulfate. Canadian Medical Association 1998;158:1327-1330.
*Krop S. Toxicology of hydrazine: a review. Arch Int Hyg 1954;9:199-204.
*Smigel K. Hydrazine sulfate used in cancer patients. Journal of the National Cancer Institute 1990 Feb 21;82(4):254.
*Memorial Sloan-Kettering Cancer Center. About Herbs: Hydrazine Sulfate. 2006. www.mskcc.org/mskcc/html/69260.cfm
*University of Texas M.D. Anderson Cancer Center. Hydrazine Sulfate Detailed Scientific Review. 2007. http://www.mdanderson.org/departments/cimer/display.cfm?id=AD1A435D-17B1-11D5-811000508B603A14&method=displayFull&pn=6EB86A59-EBD9-11D4-810100508B603A14
*Spremulli E, Wampler GL, Regelson W: Clinical study of hydrazine sulfate in advanced cancer patients. Cancer Chemother Pharmacol 3 (2): 121-4, 1979.
*Kimball RF: The mutagenicity of hydrazine and some of its derivatives. Mutat Res 39 (2): 111-26, 1977.
*Vasudeva M, Vashishat RK: Mutagenic and recombinogenic activity of hydrazine sulphate in Saccharomyces cerevisiae. Mutat Res 155 (3): 113-5, 1985.
*Toth B: Synthetic and naturally occurring hydrazines as possible cancer causative agents. Cancer Res 35 (12): 3693-7, 1975.
*Rosenkranz HS, Carr HS: Hydrazine antidepressants and isoniazid: potential carcinogens. Lancet 1 (7713): 1354-5, 1971.
*Douglas GR, Gingerich JD, Soper LM: Evidence for in vivo non-mutagenicity of the carcinogen hydrazine sulfate in target tissues of lacZ transgenic mice. Carcinogenesis 16 (4): 801-4, 1995.
*Bhide SV, D'Souza RA, Sawai MM, et al.: Lung tumour incidence in mice treated with hydrazine sulphate. Int J Cancer 18 (4): 530-5, 1976.
*Toth B: Lung tumor induction and inhibition of breast adenocarcinomas by hydrazine sulfate in mice. J Natl Cancer Inst 42 (3): 469-75, 1969. [PUBMED Abstract]
*Gold J: Proposed treatment of cancer by inhibition of gluconeogenesis. Oncology 22 (2): 185-207, 1968.
*Loprinzi CL, Goldberg RM, Su JQ, et al.: Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 12 (6): 1126-9, 1994.
*CA (Anonymous). Unproven methods of cancer management: hydrazine sulfate. CA: a Cancer Journal for Clinicians 1976;26:108-110.
*Cassileth BR. Alternative medicine handbook: a complete reference guide to alternative and complementary therapies. New York: W.W. Norton & Co., 1998:162-163.
==Weblinks==
==Weblinks==